Home / BiomarkerLive / Advisory Committee 2019

Advisory Committee 2019

Patricia Friend
Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC
Associate Professor and Program Director
Marcella Niehoff School of Nursing, Loyola University Chicago
Chicago, IL

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC, has advanced certification in oncology nursing, is board certified in advanced genetics nursing, and is licensed as an APRN-CNS (Clinical Nurse Specialist). Her areas of expertise are oncology and genomics, educational preparation of advanced practice nurses, online education, and interprofessional education and practice. Dr. Friend’s doctoral dissertation work was supported by the American Cancer Society (doctoral scholarship), and her pre-doctoral fellowship (F31) was from the National Cancer Institute. Dr. Friend’s doctoral research—examining the interactions between stress and immune responses in women undergoing diagnostic breast biopsy—was funded by the National Cancer Institute, the Oncology Nursing Foundation, and the Chicago Chapter of the Oncology Nursing Society. Dr. Friend has experience with educational training grants, and she currently leads a team of faculty supported by the NCI-sponsored Interprofessional Education Exchange (iPEX) Project, which is developing interprofessional education in palliative care.

Dr. Friend’s main area of clinical scholarship and research interest is genetics/genomics. She serves on the Genomics Advisory Board for the Oncology Nursing Society, and she is interested in improving the genomic literacy of healthcare educators, students, and clinicians. Dr. Friend has taught a Cancer Genomics course for graduate nursing students for many years.

Jennifer Godden
Jennifer Godden, PharmD
Co-Director, Oncology Precision Medicine
Advocate Aurora Health Care
Milwaukee, WI

Jennifer Godden, PharmD is the Co-Director of Oncology Precision Medicine at Advocate Aurora Health Care in Milwaukee, WI. She received her Doctor of Pharmacy degree from the University of Iowa in 2007, graduating with high distinction. Following graduation, Dr. Godden completed a PGY-1 Pharmacy Practice Residency with Aurora Health Care (AHC). She worked at AHC for an additional two as an inpatient clinical pharmacist before becoming AHC’s first PGY-2 Oncology Pharmacy Specialty Resident. After her second residency, Dr. Godden continued to work for AHC as an oncology clinical coordinator for five years before moving into her current position. Dr. Godden is board certified as an oncology pharmacist by the American College of Clinical Pharmacy and is a member of the Hematology Oncology Pharmacy Association and Pharmacy Society of Wisconsin.

Annette Kim
Annette S. Kim, MD, PhD
Associate Professor of Pathology, Harvard Medical School
Hematopathologist and Molecular Pathologist,
Brigham and Women's Hospital
Boston, MA

Annette S. Kim, MD, PhD, is an Associate Professor of Pathology at Harvard Medical School and a practicing hematopathologist and molecular pathologist at Brigham and Women's Hospital in Boston, MA. She has prior training in synthetic organic chemistry and structural biology, and she spent several years in the pharmaceutical industry before returning to academia. Since returning to clinical practice, Dr. Kim has practiced diagnostic hematopathology and molecular pathology, and she is the Associate Director of the Center for Advanced Molecular Diagnostics, in which role she has directed assay validation and quality assurance.

Dr. Kim has experience implementing, receiving funding for, and publishing on efforts in test utilization management, conducting studies on the cost-effective practice of hematopathology. She has been an active member of the Association of Molecular Pathology, serving as chair of several committees and as a member of the Executive Committee, Strategic Opportunities Committee, and Board. She also serves on the College of American Pathologists Molecular Oncology Committee. Through these societies, Dr. Kim has published key papers on myeloid mutational patterns and the performance of FDA companion diagnostics and laboratory developed assays, including the performance of next-generation sequencing assays.

Edward Kim
Edward S. Kim, MD
Chair, Solid Tumor Oncology and Investigational Therapeutics
Medical Director of Clinical Trials Office
Levine Cancer Institute, Atrium Health
Charlotte, NC

Edward S. Kim, MD, is Chair of Solid Tumor Oncology and Investigational Therapeutics, Medical Director of the Clinical Trials Office, and the Donald S. Kim Distinguished Chair for Cancer Research at the Levine Cancer Institute, Atrium Health, in Charlotte, NC. Dr. Kim was previously at the University of Texas MD Anderson Cancer Center in Houston, where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology, and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology.

Dr. Kim specializes in cancer biomarkers and novel targeted agents in treatment and prevention settings and has expertise in lung, head, and neck cancers. He has chaired the Department of Defense Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program, and he currently oversees solid tumor faculty and research development at Levine Cancer Institute.

Dr. Kim is the author or coauthor of more than 100 published articles, book chapters, and reviews in journals including Lancet, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research Cancer, and Cancer Prevention Research. His articles address cancer therapeutics and prevention with chemotherapy and novel targeted agents, with particular emphasis on lung cancer and head and neck cancer. Dr. Kim received his BS and medical degrees from the Honors Program in Medical Education at Northwestern University, completed his residency at Baylor College of Medicine, and did his fellowship in medical oncology at UT MD Anderson Cancer Center.

Scott VandenBerg
Scott VandenBerg, MD, PhD
Director, Tissue Core Facility
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Scott VandenBerg, MD, PhD, is the director of the Tissue Core Facility at UCSF Helen Diller Family Comprehensive Cancer Center, with extensive experience developing tissue-based biomarker techniques and directing biorepositories for the optimal acquisition, archiving, annotation, and custodianship of human tissue for cancer research. Dr. VandenBerg’s technical expertise in molecular morphology include immunohistochemistry/immunofluorescence and molecular in situ analyses.

Since 2008, a major emphasis of his technical research core activities has been to develop more quantitative detection of biomarkers of activated signaling pathways in a wide spectrum of human disease, focusing on cancer. His translational research focuses on the application of multiple proteomic, epigenetic, and genetic techniques for the molecular morphologic analysis of biomarkers in CNS tumor sections. The technologies include processing techniques for tissue to preserve analyte quality for RNA, DNA, and proteomics with optimal histologic quality and multiple detection modalities on tissue sections for biomarker multiplexing in heterogeneous tumors, including the genomic and proteomic characterization of prognostic markers in CNS tumors.

Dr. VandenBerg directed the establishment of a tissue technology laboratory to optimize the use of quantitative immunofluorescence detection techniques for combined IF/ISH analyses and for the multiplex analysis of inter-related signaling pathways in human tissue, focusing on cancer. Prior to joining UCSF, Dr. VandenBerg was director of the UCSD Moores Comprehensive Center Biorepository, Histopathology, and Tissue Technology Shared Resource.

Our Partners



Our Supporters

logo-abbvie-200x80 This project is supported by AbbVie, Lilly Oncology, and Merck & Co., Inc. BMS-330x80 Phase one of this project was supported by Bristol Myers Squibb.